HUTCHMED (LON:HCM) Share Price Passes Below 200-Day Moving Average - Here's What Happened

Key Points

• HUTCHMED's stock has crossed below its 200-day moving average, trading at GBX 225 ($3.02), down from GBX 230.85 ($3.10).
• The company has a debt-to-equity ratio of 11.97, indicating high leverage, alongside a market capitalization of £2.50 billion.
• HUTCHMED is a global-focused drug discovery company in China, with three oncology medicines approved for marketing in both China and the U.S.

Shares of HUTCHMED (China) Limited (LON:HCM - Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 230.85 ($3.13) and traded as low as GBX 223 ($3.02). HUTCHMED shares last traded at GBX 225 ($3.05), with a volume of 45,959 shares traded.

HUTCHMED Stock Performance

The company has a debt-to-equity ratio of 11.97, a current ratio of 2.81 and a quick ratio of 2.97. The firm has a market capitalization of £2.64 billion, a price-to-earnings ratio of -62.02 and a beta of 0.76. The firm's fifty day moving average is GBX 243.12 and its 200 day moving average is GBX 231.07.

HUTCHMED Company Profile

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S. We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China. HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange's AIM market (Nasdaq/AIM:HCM; HKEX:13).